Xiang Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiang Wang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Xin-Xin Chen
Department of Burn Surgery, The First Hospital of Jilin University, Jilin University
2 shared publicationsYun-Qing Hou
Department of Cardiovascular Disease, The First Hospital of Jilin University, Jilin University
2 shared publicationsMuli Wu
Department of Cardiovascular Disease Center First Affiliated Hospital of Shantou University Shantou University Shantou China
1 shared publication- Qi Zhou
Chinese Academy of Sciences
1 shared publication Wei Wang
Outpatient Department of Pediatrics, The First Hospital of Jilin University, Jilin University, Changchun, China
1 shared publication- Xin-Xin Chen
Department of Burns First Hospital of Jilin University Jilin University Changchun China
1 shared publication
Latest Publications
- Open Access
- 6 March 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1766502
Bridging innate immunity and iron-dependent death: the interplay between cyclic GMP–AMP synthase–stimulator of interferon genes nexus and ferroptosis in cancer and inflammation
The cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway and ferroptosis have emerged as fundamental biological mechanisms that converge in regulating cellular homeostasis and disease pathogenesis. As a central component of innate immunity, the cGAS–STING axis detects cytosolic double-stranded DNA through cGAS-mediated synthesis of 2′3′-cyclic GMP–AMP, subsequently triggering STING-dependent activation of the TBK1–IRF3 and nuclear factor-κB signaling cascades. Ferroptosis, an iron-catalyzed form of regulated cell death, is characterized by the accumulation of phospholipid hydroperoxide due to compromised antioxidant activity and dysregulated iron metabolism. Accumulating evidence has revealed the intricate crosstalk between these pathways. This review systematically explores the structural and biochemical bases of both pathways, identifies key bridging molecules that mediate their interactions, and discusses therapeutic strategies targeting this crosstalk, particularly in cancer treatment.
- 6 March 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1766502
Open AccessBridging innate immunity and iron-dependent death: the interplay between cyclic GMP–AMP synthase–stimulator of interferon genes nexus and ferroptosis in cancer and inflammation
The cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway and ferroptosis have emerged as fundamental biological mechanisms that converge in regulating cellular homeostasis and disease pathogenesis. As a central component of innate immunity, the cGAS–STING axis detects cytosolic double-stranded DNA through cGAS-mediated synthesis of 2′3′-cyclic GMP–AMP, subsequently triggering STING-dependent activation of the TBK1–IRF3 and nuclear factor-κB signaling cascades. Ferroptosis, an iron-catalyzed form of regulated cell death, is characterized by the accumulation of phospholipid hydroperoxide due to compromised antioxidant activity and dysregulated iron metabolism. Accumulating evidence has revealed the intricate crosstalk between these pathways. This review systematically explores the structural and biochemical bases of both pathways, identifies key bridging molecules that mediate their interactions, and discusses therapeutic strategies targeting this crosstalk, particularly in cancer treatment.
- Open Access
- 18 December 2025
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 26 (1) , 3
FTO-Mediated Mitigation of Ferroptosis Occurs in an ACSL4-Dependent Manner in Diabetic Cardiomyopathy
Considering the global prevalence of diabetes, diabetic cardiomyopathy (DCM), as a significant diabetes complication, remains a major human challenge; while previous studies have identified ferroptosis as an important underlying mechanism, the unclear regulatory mechanisms hamper the development of therapy for DCM. In this study, we reveal that the expression of the fat mass and obesity-associated protein (FTO) is downregulated in DCM. Overexpression of FTO was found to enhance cardiac function by inhibiting ferroptosis. Mechanistically, acyl - CoA synthetase long - chain family 4 (ACSL4), a key positive mediator of ferroptosis, was identified as a direct target of FTO. The ameliorative effect of FTO was contingent upon the inhibition of ACSL4, and FTO-mediated mitigation of ferroptosis occurs in an ACSL4-dependent manner in DCM. Furthermore, we demonstrate that nicotinamide mononucleotide and sulforaphane can synergistically suppress ferroptosis by targeting distinct pathways, thereby better alleviating cardiac dysfunction. Collectively, our findings uncover an FTO - ACSL4 regulatory axis that plays a crucial role in the pathogenesis of DCM, offering valuable insights for the development of therapeutic strategies against DCM. Graphical abstract Schematic representation of FTO-mediated mitigation of ferroptosis occurs in an ACSL4-dependent manner in diabetic cardiomyopathy (DCM). FTO is downregulated in DCM, which leads to increased methylation of Acsl4 transcripts. This epigenetic modification results in elevated levels of Acsl4 mRNA and ACSL4 protein, which subsequently induces lipid peroxidation and ferroptosis. The attenuation of FTO-mediated ferroptosis is thus achieved through an ACSL4-dependent manner. Importantly, based on our previous study, NMN targeting FTO combined with SFN targeting NRF2 could synergistically inhibit ferroptosis, reducing lipid peroxidation and ferroptosis, and ultimately ameliorating DCM. DM, diabetes mellitus; FTO, fat mass and obesity-associated protein; DCM, diabetic cardiomyopathy; ACSL4, acyl-CoA synthetase long-chain family member 4; SLC7A11, solute carrier family 7 member 11; NMN, mononucleotide; SFN, sulforaphane
- 18 December 2025
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 26 (1) , 3
Open AccessFTO-Mediated Mitigation of Ferroptosis Occurs in an ACSL4-Dependent Manner in Diabetic Cardiomyopathy
Considering the global prevalence of diabetes, diabetic cardiomyopathy (DCM), as a significant diabetes complication, remains a major human challenge; while previous studies have identified ferroptosis as an important underlying mechanism, the unclear regulatory mechanisms hamper the development of therapy for DCM. In this study, we reveal that the expression of the fat mass and obesity-associated protein (FTO) is downregulated in DCM. Overexpression of FTO was found to enhance cardiac function by inhibiting ferroptosis. Mechanistically, acyl - CoA synthetase long - chain family 4 (ACSL4), a key positive mediator of ferroptosis, was identified as a direct target of FTO. The ameliorative effect of FTO was contingent upon the inhibition of ACSL4, and FTO-mediated mitigation of ferroptosis occurs in an ACSL4-dependent manner in DCM. Furthermore, we demonstrate that nicotinamide mononucleotide and sulforaphane can synergistically suppress ferroptosis by targeting distinct pathways, thereby better alleviating cardiac dysfunction. Collectively, our findings uncover an FTO - ACSL4 regulatory axis that plays a crucial role in the pathogenesis of DCM, offering valuable insights for the development of therapeutic strategies against DCM. Graphical abstract Schematic representation of FTO-mediated mitigation of ferroptosis occurs in an ACSL4-dependent manner in diabetic cardiomyopathy (DCM). FTO is downregulated in DCM, which leads to increased methylation of Acsl4 transcripts. This epigenetic modification results in elevated levels of Acsl4 mRNA and ACSL4 protein, which subsequently induces lipid peroxidation and ferroptosis. The attenuation of FTO-mediated ferroptosis is thus achieved through an ACSL4-dependent manner. Importantly, based on our previous study, NMN targeting FTO combined with SFN targeting NRF2 could synergistically inhibit ferroptosis, reducing lipid peroxidation and ferroptosis, and ultimately ameliorating DCM. DM, diabetes mellitus; FTO, fat mass and obesity-associated protein; DCM, diabetic cardiomyopathy; ACSL4, acyl-CoA synthetase long-chain family member 4; SLC7A11, solute carrier family 7 member 11; NMN, mononucleotide; SFN, sulforaphane
- Open Access
- 1 January 2024
- Published by Compuscript, Ltd. in Cardiovascular Innovations and Applications
- Vol. 9 (1) , 951
Current Outcomes after Revascularization for Coronary Very Late Stent Thrombosis
Objective: Limited data are available regarding current outcomes after revascularization for angiographically confirmed very late stent thrombosis (VLST). Therefore, this study investigated the current outcomes of patients with VLST and the risk factors for major adverse cardiovascular events (MACE). Methods: Consecutive patients who underwent revascularization for angiographically confirmed VLST between January 2014 and January 2016 were enrolled in this study. The patients were divided into two groups according to the occurrence of MACE during follow-up. The clinical and interventional parameters between groups were compared. Results: A total of 564 patients with an average age of 61.61 ± 10.71 years were enrolled. Eight patients died during hospitalization. MACE occurred in 100 patients after a mean follow-up of 620 days. The total MACE rate was 35.46%, and Kaplan-Meier survival analysis indicated an estimated MACE-free survival rate of 22%. Multivariable Cox regression analysis revealed that left ventricular ejection fraction and peak troponin I at VLST onset were independent predictors of MACE. Conclusions: Long-term outcomes after revascularization for VLST remained unfavorable. Left ventricular ejection fraction and peak troponin I at the onset of VLST were independent risk factors for poor prognosis.
- 1 January 2024
- Published by Compuscript, Ltd. in Cardiovascular Innovations and Applications
- Vol. 9 (1) , 951
Open AccessCurrent Outcomes after Revascularization for Coronary Very Late Stent Thrombosis
Objective: Limited data are available regarding current outcomes after revascularization for angiographically confirmed very late stent thrombosis (VLST). Therefore, this study investigated the current outcomes of patients with VLST and the risk factors for major adverse cardiovascular events (MACE). Methods: Consecutive patients who underwent revascularization for angiographically confirmed VLST between January 2014 and January 2016 were enrolled in this study. The patients were divided into two groups according to the occurrence of MACE during follow-up. The clinical and interventional parameters between groups were compared. Results: A total of 564 patients with an average age of 61.61 ± 10.71 years were enrolled. Eight patients died during hospitalization. MACE occurred in 100 patients after a mean follow-up of 620 days. The total MACE rate was 35.46%, and Kaplan-Meier survival analysis indicated an estimated MACE-free survival rate of 22%. Multivariable Cox regression analysis revealed that left ventricular ejection fraction and peak troponin I at VLST onset were independent predictors of MACE. Conclusions: Long-term outcomes after revascularization for VLST remained unfavorable. Left ventricular ejection fraction and peak troponin I at the onset of VLST were independent risk factors for poor prognosis.